Allergy Therapeutics plc (LON:AGY – Get Free Report) reached a new 52-week high during trading on Thursday . The stock traded as high as GBX 9.50 and last traded at GBX 8.60, with a volume of 242488 shares traded. The stock had previously closed at GBX 8.60.
Allergy Therapeutics Price Performance
The company has a quick ratio of 1.48, a current ratio of 1.63 and a debt-to-equity ratio of 835.48. The firm’s 50 day simple moving average is GBX 8.30 and its 200 day simple moving average is GBX 7.93. The company has a market cap of £528.16 million, a price-to-earnings ratio of -11.94, a price-to-earnings-growth ratio of -30.70 and a beta of 1.40.
Allergy Therapeutics Company Profile
Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries.
Featured Articles
- Five stocks we like better than Allergy Therapeutics
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Applied Materials: Up 40% in 2025 With Room to Run Long-Term
- High Dividend REITs: Are They an Ideal Way to Diversify?
- onsemi Places a $6 Billion Bet on Its Own Stock
- What is a SEC Filing?
- HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?
Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
